June 17th, 2016
Episode 1028 of 1594 episodes
Over 2700 people in England may be affected if health watchdog NICE decide not to approve a "breakthrough" treatment for people with cystic fibrosis for use on the NHS. The drug Orkambi, which costs 104,000 a year per patient, has been shown to improve lung function and respiratory symptoms in people with cystic fibrosis, but NICE said the benefits were modest. Fourteen-year-old Clara Mann, who has cystic fibrosis, and her father Nicholas Mann discuss the benefits the drug has had on her life. (Image: Child with nurse. Credit: SPL)
The Art of Charm Podcast is where self-motivated guys and gals, just like you, come to learn from a diverse mix of experienced mentors, including the world's best professional and academic minds, scientists, relationship experts, entrepreneurs, bestselling authors, and other badasses. This show will make you a better networker, better connector, and -- most important -- a better thinker.